CANY
MRTX

Caxton Associates (New York)’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Caxton Associates (New York)’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,694
Closed -$300K – 698
2021
Q3 		$300K Sell
1,694
-1,815
-52% -$292K 0.03% 311
2021
Q2 		$567K Buy
+3,509
New +$563K 0.06% 153

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Caxton Associates (New York)'s MRTX Position: Q4 2021 in Review

Caxton Associates (New York) sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 1,694 shares — an estimated $300K sold.

Caxton Associates (New York) first reported a position in MRTX in Q2 2021 and held it in 2 quarters. The position peaked at $567K in Q2 2021. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

  • Caxton Associates (New York) reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Caxton Associates (New York) sold 1,694 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $300K.
  • Caxton Associates (New York) first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Caxton Associates (New York)'s Mirati Therapeutics, Inc. Common Stock position peaked at $567K in Q2 2021.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Caxton Associates (New York)'s 13F filing for Q4 2021, filed 14 Feb 2022.